A protein kinase is an enzyme that phosphorlates other proteins. Phosphorylation normally consequences in a functional alteration of the mark protein by altering its enzyme activity, cellular location, or association with other proteins [ 1 ] . The cistron household encoding protein kinases represents the most common human transforming genes. Furthermore, mutated and activated protein kinases have been determined to be good marks for the development of new marks for malignant neoplastic disease therapies [ 4 ] . Evidence has established that several different signifiers of protein kinase fail to modulate decently in many malignant neoplastic disease types, and it has been known that protein kinases play of import functions in modulating most cellular maps such as cell growing, programmed cell death, DNA harm fix, cell motility, and response to the microenvironment. This research paper will concentrate on the potency of protein kinase being used as chemotherapeutic marks in malignant neoplastic disease intervention such as chest malignant neoplastic disease every bit good as it will foreground recent surveies in the development of protein kinase inhibitors in chest malignant neoplastic disease cells.
Protein Kinase D in Breast Cancer
Emerging as a major participant in cell proliferation, endurance, motility, and angiogenesis tracts, it is no surprise that protein kinases has late received a batch of attending as a possible mark in the intervention of many types of malignant neoplastic disease such as chest malignant neoplastic disease.
Protein kinase D ( PKD ) , the founding member of a new household of serine/threonine protein kinases, occupies a alone place in the signal transduction tracts initiated by DAG and PKC [ 1 ] . PKD enzymes were foremost studied in the context of chest malignant neoplastic disease over a decennary ago [ 4 ] . Despite this early start, the mechanisms through which PKD contributes to breast malignant neoplastic disease patterned advance are non yet clear. Analysis of invasive human chest tumours has revealed that protein Kinase D look is downregulated in infiltrating ductal carcinoma compared to normal chest tissue [ 5 ] . Bowden and coworkers [ 4 ] studied cistron look utilizing transcriptional microarray of normal chest tissue and of early and advanced-stage chest tumours and shown that there was a decrease of the look of protein kinase D correlating with increased invasiveness and malignant neoplastic disease patterned advance [ 4 ] .
Functionally, surveies look intoing the function of protein kinase in chest malignant neoplastic disease patterned advance have focused on the procedures of invasion and adhesion. Equally early as 1999, Bowden and co-workers [ 4 ] described an interaction between protein kinase, paxillin, and cortactin at sites of invadopodia in chest malignant neoplastic disease cells. Invadopodia are actin-containing bulges that extend outward into the extracellular matrix ( ECM ) and take part in debasement of the ECM [ 6 ] . ECM is a filiform construction of glycoproteins and proteoglycans that is attached to the cell surface and provides cells with anchorage, grip for motion, and positional acknowledgment [ 1 ] . This interaction, present in invasive chest malignant neoplastic disease cells but non in non-invasive lines, suggested that protein kinase D may modulate the map or formation of the paxillin/cortactin composite to advance invasion.
Multiple separate surveies have strongly supported an opposing function for protein kinase D in chest malignant neoplastic disease cell invasion and adhesion. Surveies by Eiseler and co-workers [ 5 ] have shown that invasion in 2D and 3D environments was reduced with look of a constitutively active protein kinase D mutation in chest malignant neoplastic disease cells. Based on mechanistic debate, it has been suggested that the ordinance of adhesion and invasion by PKD1 may be related to MMP look. MMP is an enzyme that degrades matrix proteins. In chest malignant neoplastic disease, MMP in peculiar has been identified as an index of possible malignance [ 7 ] . Therefore, it is possible that protein kinase D may suppress chest malignant neoplastic disease invasion and metastasis through ordinance of MMP look.
Signing Mechanism of Protein Kinase D
Emerging grounds links PKD to a diverse set of signal transduction tracts involved in tumour development and malignant neoplastic disease patterned advance ( Fig. 1 ) . PKD has many possible functions every bit good as signalling mechanism in cancer-associated responses, such as ; proliferations, endurance and programmed cell death [ 3 ] .
Uncontrolled cell growing and opposition to programmed cell death are among the trademarks of malignant neoplastic disease development. Mechanistically, PKD has been linked to several tracts known to command cell proliferation, most notably the extracellular signal regulated kinase ( ERK ) signaling pathway [ 3 ] . Inhibition of PKD look and activity has been shown to rarefy ERK signaling, while overexpression of PKD has been shown to potentiate ERK
Fig. 1. PKD has been implicated in the ordinance of multiple cancer-promoting tracts. PKC-mediated activation of PKD has been shown to modulate such cellular maps as
proliferation, programmed cell death, angiogenesis, migration, and invasion. Dysregulation of these cardinal tracts can take to the development, patterned advance, and metastasis of malignant neoplastic disease.
activity in response to growing factors in multiple cell types including endothelial cells [ 5 ] .
Surveies from Wong and co-workers [ 3 ] have described PKD as a powerful booster of cell growing and proliferation in multiple cellular systems, proposing that PKD may perchance lend to the malignant neoplastic disease phenotype. Cancer is a group of diseases characterized by aberrances in cellular growing, proliferation and endurance tracts, ensuing in tumour formation and uncontrolled enlargement of malignant neoplastic disease cells [ 1 ] . Kinases such as c-Src, c-Abl, mitogen activated protein ( MAP ) kinase, phosphotidylinositol-3-kinase ( PI3K ) AKT, and the cuticular growing factor ( EGF ) receptor are normally activated in malignant neoplastic disease cells, and are known to lend to tumorigenesis. Many of these occur in the same signalling tract [ 2 ] . Research groups have developed several ways to aim these enzymes therapeutically, such as with antibodies or little molecules that block kinase-substrate interaction, or that inhibit the enzyme ‘s adenosine triphosphate ( ATP ) adhering site. A figure of kinase inhibitors have therefore already been developed and approved for malignant neoplastic disease intervention. The possible for aiming kinases in the intervention of malignant neoplastic disease was the subject of the Keystone Symposium “ Protein Kinases and Cancer: The Promise of Molecular Based Therapies ” late held in Tahoe City, California [ 2 ] . In the gap reference, Robert Wittes [ 2 ] , of the Memorial Sloan-Kettering Cancer Center, NY, discussed the pros and cons of aiming kinases in malignant neoplastic disease patients. One of the chief pros was that kinase inhibitors designed to barricade the enzyme ‘s ATP adhering site can hold wide specificity such as that with imatinib that non merely inhibits the tyrosine kinase c-Abl, but besides c-Kit and the platelet-derived growing factor ( PDGF ) receptor tyrosine kinases. So it can be used to handle many types of tumours associated with activation of these signalling molecules [ 2 ] .
Protein Kinase D as a chemotherapeutic mark
Immunohistochemistry analysis of multiple types of human malignant lymphoma have revealed variable look of protein kinase and activity [ 8 ] . T. Eiseler and co-workers suggest in their research experiment that protein kinase look frequently were really similar to the normal lymph tissue from which the peculiar tumours were derived. This survey suggests that while protein kinase is expressed in many types of lymphoma, it may non be involved in patterned advance of the disease ; nevertheless, more surveies are required to back up these decisions [ 5 ] .
In decision extended grounds indicates that protein kinase look is deregulated in multiple malignant neoplastic disease types and plays an active function in a assortment of cancer-associated biological procedures including proliferation, endurance, programmed cell death, migration, invasion, and angiogenesis, doing protein kinase an attractive mark for drug development [ 3 ] . To day of the month, there have been no studies of familial protein kinase carnal theoretical accounts related to chest malignant neoplastic disease. However, despite this, pharmacological suppression of protein kinase has now shown to be effectual at stamp downing growing of pancreatic tumour heterografts [ 15 ] , which greatly enhances the cogency of protein kinase as a chemotherapeutic mark.
[ 1 ] hypertext transfer protocol: //en.wikipedia.org/wiki/ , Definitions for biochemical footings, accessed Nov. 8th, 2010.
[ 2 ] S. Fogarty, D.G. Hardie, Development of protein kinase activators: AMPK as a mark in metabolic upsets and malignant neoplastic disease, Biochimica et Biophysica Acta ( BBA ) – Proteins & A ; Proteomicss, Volume 1804, Issue 3, March 2010, Pages 581-591
[ 3 ] C. Wong, Z.G. Jin, Protein kinase C-dependent protein kinase D activation modulates ERK signal tract and endothelial cell proliferation by vascular endothelial growing factor, J. Biol. Chem. 280 ( 2005 ) 33262-33269
[ 4 ] E.T. Bowden, M. Barth, D. Thomas, R.I. Glazer and S.C. Mueller, An invasion-related composite of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix debasement, Oncogene 18 ( 1999 ) , pp. 4440-4449.
[ 5 ] T. Eiseler, H. Doppler, I.K. Yan, S. Goodison and P. Storz, Protein kinase D1 regulates matrix metalloproteinase look and inhibits chest malignant neoplastic disease cell invasion, Breast Cancer Res. 11 ( 2009 ) , p. R13.
[ 6 ] S.S. Stylli, A.H. Kaye and P. Lock, Invadopodia: at the cutting border of tumour invasion, J. Clin. Neurosci. 15 ( 2008 ) , pp. 725-737.
[ 7 ] A. Jezierska and T. Motyl, Matrix metalloproteinase-2 engagement in chest malignant neoplastic disease patterned advance: a mini-review, Med. Sci. Monit. 15 ( 2009 ) , pp. RA32-RA40.
[ 8 ] K.B. Harikumar, A.B. Kunnumakkara, N. Ochi, Z. Tong, A. Deorukhkar, B. Sung, L. Kelland, S. Jamieson, R. Sutherland, T. Raynham, M. Charles, A. Bagherazadeh, C. Foxton, A. Boakes, M. Farooq, D. Maru, P. Diagaradjane, Y. Matsuo, J. Sinnett-Smith, J. Gelovani, S. Krishnan, B.B. Aggarwal, E. Rozengurt, C.R. Ireson and S. Guha, A fresh small-molecule inhibitor of protein kinase D blocks pancreatic malignant neoplastic disease growing in vitro and in vivo, Mol. Cancer Ther. 9 ( 2010 ) , pp. 1136-1146.
[ 9 ] A A Sushovan Guha, Suebpong Tanasanvimon, James Sinnett-Smith, Enrique Rozengurt, Role of protein kinase D signaling in pancreatic malignant neoplastic disease, Biochemical Pharmacology ( 2010 ) .